{"product_id":"6826hk-business-model-canvas","title":"Shanghai Haohai Biological Technology Co., Ltd. (6826.HK): Canvas Business Model","description":"\u003cp\u003eShanghai Haohai Biological Technology Co., Ltd. stands at the forefront of biopharmaceutical innovation, expertly navigating the complex world of biotechnology. With a robust Business Model Canvas that outlines its strategic partnerships, key activities, and diverse revenue streams, Haohai is redefining the standards of quality and compliance in the medical field. Dive into the intricacies of their business model and discover how this pioneering company is shaping the future of healthcare.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eShanghai Haohai Biological Technology Co., Ltd. relies heavily on strategic partnerships to enhance its market position and operational capabilities. Below are key elements of their partnership framework.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eHaohai has established collaborations with various research institutions to innovate and develop new products. Notably, the company worked with institutions like Fudan University and Shanghai Jiao Tong University, aiming to leverage academic research for biotechnology advancements.\u003c\/p\u003e\n\u003cp\u003eIn 2022, Haohai reported that \u003cstrong\u003e30%\u003c\/strong\u003e of its R\u0026amp;D projects were directly influenced by partnerships with these research institutions, contributing to a reported R\u0026amp;D expenditure of \u003cstrong\u003eRMB 180 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eQuality raw materials are fundamental to the production of Haohai's biological products. The company partners with top-tier suppliers, ensuring the consistency and quality of inputs.\u003c\/p\u003e\n\u003cp\u003eIn 2022, Haohai’s procurement costs amounted to \u003cstrong\u003eRMB 250 million\u003c\/strong\u003e, with raw materials representing approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total costs. Key suppliers include those based in China and international markets, ensuring a diversified supply chain.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners\u003c\/h3\u003e\n\u003cp\u003eHaohai has established a robust network of distribution partners to efficiently deliver its products both domestically and internationally. The partnership with Sinopharm, one of China’s largest pharmaceutical distributors, has been notable.\u003c\/p\u003e\n\u003cp\u003eAs of Q2 2023, Haohai reported that distribution partnerships contributed to a \u003cstrong\u003e25%\u003c\/strong\u003e increase in sales volume year-over-year, equating to revenues of \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e. The company also expanded its international distribution reach in the Asia-Pacific region to enhance market penetration.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003cp\u003eMaintaining compliance with regulatory standards is crucial for Haohai's operations. The company collaborates with various regulatory bodies, including the National Medical Products Administration (NMPA) in China.\u003c\/p\u003e\n\u003cp\u003eIn recent years, Haohai has invested approximately \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e in regulatory compliance initiatives. This investment ensures timely approvals for new products, which is essential for maintaining a competitive edge in the biotech sector.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePartnership Type\u003c\/th\u003e\n    \u003cth\u003eDescription\u003c\/th\u003e\n    \u003cth\u003eImpact on Business\u003c\/th\u003e\n    \u003cth\u003e2022 Financial Data (RMB)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n    \u003ctd\u003eCollaborations with universities for R\u0026amp;D\u003c\/td\u003e\n    \u003ctd\u003eContributes to innovation and product development\u003c\/td\u003e\n    \u003ctd\u003eR\u0026amp;D Expenditure: 180 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n    \u003ctd\u003eSuppliers ensuring quality raw materials\u003c\/td\u003e\n    \u003ctd\u003eCritical for cost management and product quality\u003c\/td\u003e\n    \u003ctd\u003eProcurement Costs: 250 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistribution Partners\u003c\/td\u003e\n    \u003ctd\u003ePartnerships for sales and distribution\u003c\/td\u003e\n    \u003ctd\u003eIncreases sales volume and market reach\u003c\/td\u003e\n    \u003ctd\u003eRevenues: 800 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Bodies\u003c\/td\u003e\n    \u003ctd\u003eCompliance and product approval\u003c\/td\u003e\n    \u003ctd\u003eEnsures market entry and operational legality\u003c\/td\u003e\n    \u003ctd\u003eCompliance Investment: 50 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eBy effectively leveraging these key partnerships, Shanghai Haohai Biological Technology Co., Ltd. solidifies its position in the biotechnology market, driving both innovation and operational efficiency.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eResearch and Development (R\u0026amp;D) for New Biotechnology\u003c\/strong\u003e is a cornerstone of Shanghai Haohai's operations. In 2022, the company invested approximately \u003cstrong\u003eRMB 177 million\u003c\/strong\u003e in R\u0026amp;D, representing about \u003cstrong\u003e15%\u003c\/strong\u003e of its total revenue. The focus areas include the development of innovative biopharmaceutical products and advanced biotechnology solutions, including monoclonal antibodies and recombinant proteins.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProduction of Biopharmaceutical Products\u003c\/strong\u003e is another critical activity. The company operates state-of-the-art manufacturing facilities, with an annual production capacity exceeding \u003cstrong\u003e50 million\u003c\/strong\u003e units for various biopharmaceuticals. In 2022, Shanghai Haohai's production revenue reached around \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, driven by growing demands in both domestic and international markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eProduction Capacity (Units)\u003c\/th\u003e\n        \u003cth\u003eProduction Revenue (RMB)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e40 million\u003c\/td\u003e\n        \u003ctd\u003eRMB 1 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e50 million\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.2 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023 (forecast)\u003c\/td\u003e\n        \u003ctd\u003e60 million\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.5 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eQuality Assurance and Control\u003c\/strong\u003e are essential for maintaining the integrity of biopharmaceutical products. The company follows stringent quality management systems, with over \u003cstrong\u003e200 quality control personnel\u003c\/strong\u003e employed. In 2022, Shanghai Haohai underwent several audits and successfully achieved compliance with \u003cstrong\u003eISO 9001\u003c\/strong\u003e and \u003cstrong\u003eGMP\u003c\/strong\u003e standards, enhancing its credibility in both local and global markets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMarketing and Branding Strategies\u003c\/strong\u003e form a vital part of Shanghai Haohai's approach to growth. In 2022, the firm allocated approximately \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e to marketing initiatives aimed at expanding brand awareness and customer outreach. The company's marketing strategy utilizes digital channels, partnerships with healthcare institutions, and participation in international biotech exhibitions to promote its products.\u003c\/p\u003e\n\n\u003cp\u003eThe company recorded a \u003cstrong\u003e25%\u003c\/strong\u003e increase in brand recognition as measured by customer surveys conducted in the same year, reflecting the effectiveness of its marketing campaigns.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eShanghai Haohai Biological Technology Co., Ltd. relies on a range of key resources to create and deliver medical solutions, particularly in the field of ophthalmology and other health sectors. The following are the essential assets that underpin the company's operations.\u003c\/p\u003e\n\n\u003ch3\u003eState-of-the-art Labs\u003c\/h3\u003e\n\u003cp\u003eHaohai has invested significantly in advanced laboratory facilities to support its research and development activities. The company operates several laboratories equipped with cutting-edge technology for drug development and testing. As of the latest financial reports, Haohai has allocated approximately \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e (about \u003cstrong\u003e$23 million\u003c\/strong\u003e) to upgrade its laboratory infrastructure.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Scientific Team\u003c\/h3\u003e\n\u003cp\u003eThe backbone of Haohai's innovation is its skilled scientific team, comprising over \u003cstrong\u003e300 employees\u003c\/strong\u003e with expertise in various disciplines including molecular biology, pharmacology, and clinical medicine. In the most recent hiring phase, the company increased its workforce by \u003cstrong\u003e20% in the past year\u003c\/strong\u003e, reflecting its commitment to enhancing its research capabilities.\u003c\/p\u003e\n\n\u003ch3\u003eStrong Patent Portfolio\u003c\/h3\u003e\n\u003cp\u003eHaohai boasts a robust patent portfolio, consisting of over \u003cstrong\u003e80 active patents\u003c\/strong\u003e globally. These patents cover key innovations in drug formulations and medical devices. In the past year, the company has filed for \u003cstrong\u003e10 new patents\u003c\/strong\u003e, demonstrating its focus on protecting intellectual property and sustaining competitive advantage.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eHaohai operates state-of-the-art manufacturing facilities that meet international standards. The company has a production capacity exceeding \u003cstrong\u003e5 million units per year\u003c\/strong\u003e for its ophthalmic products. The latest financials indicate that the manufacturing segment generated revenue of approximately \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e (around \u003cstrong\u003e$123 million\u003c\/strong\u003e) in the previous fiscal year.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eResource Type\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eInvestment\/Capacity\u003c\/th\u003e\n        \u003cth\u003eLatest Financial Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLaboratories\u003c\/td\u003e\n        \u003ctd\u003eAdvanced R\u0026amp;D labs for drug development\u003c\/td\u003e\n        \u003ctd\u003eRMB 150 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eScientific Team\u003c\/td\u003e\n        \u003ctd\u003eOver 300 skilled employees\u003c\/td\u003e\n        \u003ctd\u003e+20% workforce increase\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatents\u003c\/td\u003e\n        \u003ctd\u003eStrong portfolio with 80+ active patents\u003c\/td\u003e\n        \u003ctd\u003e10 new patents filed\u003c\/td\u003e\n        \u003ctd\u003ePotential revenue increase through IP\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eState-of-the-art production facilities\u003c\/td\u003e\n        \u003ctd\u003eCapacity of 5 million units\/year\u003c\/td\u003e\n        \u003ctd\u003eRMB 800 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese resources are critical to Haohai's mission of delivering innovative biological products and sustaining its competitive position in the biotechnology market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-quality biopharmaceuticals\u003c\/strong\u003e are at the core of Shanghai Haohai Biological Technology’s offerings. In 2022, the company's revenue from biopharmaceutical products reached approximately \u003cstrong\u003e¥1.5 billion\u003c\/strong\u003e, driven by an increase in both domestic and international sales. The company specializes in producing high-purity hyaluronic acid, which is crucial for a variety of medical applications, ranging from ophthalmic surgery to cosmetic enhancements.\u003c\/p\u003e\n\n\u003cp\u003eThe production process adheres to strict international standards, ensuring that their products meet the quality expectations of healthcare providers and patients alike. For instance, the company has obtained \u003cstrong\u003eISO 13485\u003c\/strong\u003e certification, further cementing its reputation for high-quality manufacturing and safety compliance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative medical solutions\u003c\/strong\u003e are another pillar of Haohai's value proposition. Recent advancements in the company's research and development have led to new product launches, such as the innovative hyaluronic acid-based eye drops introduced in mid-2023. This product alone generated a revenue of around \u003cstrong\u003e¥300 million\u003c\/strong\u003e within its first year, illustrating the strong market demand for pioneering healthcare solutions.\u003c\/p\u003e\n\n\u003cp\u003eHaohai also invests heavily in R\u0026amp;D, with approximately \u003cstrong\u003e15%\u003c\/strong\u003e of its annual revenue allocated to this area, highlighting its commitment to innovation. In 2023, the company filed for \u003cstrong\u003e10 patents\u003c\/strong\u003e related to biopharmaceutical products, further reinforcing its position in an increasingly competitive market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory compliance\u003c\/strong\u003e is a strategic advantage for Shanghai Haohai Biological Technology. The company has successfully navigated the stringent pharmaceutical regulations in China, maintaining compliance with both the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). As of 2023, over \u003cstrong\u003e60%\u003c\/strong\u003e of its products have received international approvals, allowing access to global markets and enhancing the brand's credibility.\u003c\/p\u003e\n\n\u003cp\u003eThe consistent adherence to regulatory standards minimizes risks associated with product recalls and legal challenges, ensuring a stable operational environment. In 2022, the company reported zero non-compliance incidents, a testament to its robust compliance framework.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCustomized customer solutions\u003c\/strong\u003e form a crucial part of Haohai’s engagement with its clients. The company works closely with healthcare providers to tailor solutions that meet specific needs, particularly in the fields of surgery and dermatology. Surveys indicate that more than \u003cstrong\u003e80%\u003c\/strong\u003e of their clients have rated their customized services as “excellent,” showcasing strong customer satisfaction.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, the company has introduced a flexible pricing model that accommodates different customer needs, thus widening its market reach. A recent analysis shows that revenue from customized solutions contributed to approximately \u003cstrong\u003e25%\u003c\/strong\u003e of total sales in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eValue Proposition\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHigh-quality biopharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eSpecializes in high-purity hyaluronic acid\u003c\/td\u003e\n        \u003ctd\u003eRevenue: ¥1.5 billion (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative medical solutions\u003c\/td\u003e\n        \u003ctd\u003eNew product launches and R\u0026amp;D investment\u003c\/td\u003e\n        \u003ctd\u003eRevenue from eye drops: ¥300 million; 15% R\u0026amp;D allocation\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory compliance\u003c\/td\u003e\n        \u003ctd\u003eCompliance with NMPA and FDA standards\u003c\/td\u003e\n        \u003ctd\u003eOver 60% products with international approvals; zero non-compliance incidents (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCustomized customer solutions\u003c\/td\u003e\n        \u003ctd\u003eFlexible pricing and tailored solutions\u003c\/td\u003e\n        \u003ctd\u003e25% of total sales from customized solutions (2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eShanghai Haohai Biological Technology Co., Ltd. has developed a multi-faceted approach to customer relationships, focusing on customer acquisition, retention, and growth through various strategies.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Customer Support\u003c\/h3\u003e\n\u003cp\u003eHaohai Biological has invested significantly in dedicated customer support to address client needs promptly. In their 2022 annual report, the company allocated approximately \u003cstrong\u003eRMB 15 million\u003c\/strong\u003e to enhance its customer service operations. The support team is trained to handle inquiries related to product specifications, delivery times, and technical assistance, resulting in a customer satisfaction score of \u003cstrong\u003e92%\u003c\/strong\u003e based on internal surveys.\u003c\/p\u003e\n\n\u003ch3\u003ePersonalized Consultation\u003c\/h3\u003e\n\u003cp\u003eThe firm offers personalized consultation services, particularly to healthcare institutions and research organizations. This service includes tailored recommendations for product applications and usage, facilitating a deeper engagement with their clients. In 2022, personalized consultations accounted for \u003cstrong\u003e30%\u003c\/strong\u003e of their total sales, generating revenue of approximately \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\u003cp\u003eHaohai Biological has developed a loyalty program to reward repeat customers. This program includes tiered benefits such as discounts, early access to new products, and exclusive webinars. The company reported that loyalty program members increased their annual purchase amounts by an average of \u003cstrong\u003e25%\u003c\/strong\u003e compared to non-members. As of 2022, the program had approximately \u003cstrong\u003e10,000\u003c\/strong\u003e active participants.\u003c\/p\u003e\n\n\u003ch3\u003eContinuous Feedback Loops\u003c\/h3\u003e\n\u003cp\u003eThe organization employs continuous feedback loops to enhance customer relationships and improve products. Surveys are distributed post-purchase, and clients are encouraged to provide input on product performance and service quality. In their latest data from the first quarter of 2023, they reported a feedback response rate of \u003cstrong\u003e45%\u003c\/strong\u003e, with insights leading to a redesign of two key products, projected to increase sales by \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Relationship Strategy\u003c\/th\u003e\n    \u003cth\u003eInvestment\/Revenue\u003c\/th\u003e\n    \u003cth\u003eImpact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDedicated Customer Support\u003c\/td\u003e\n    \u003ctd\u003eRMB 15 million\u003c\/td\u003e\n    \u003ctd\u003eCustomer satisfaction score of 92%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePersonalized Consultation\u003c\/td\u003e\n    \u003ctd\u003eRMB 200 million\u003c\/td\u003e\n    \u003ctd\u003e30% of total sales\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e25% increase in purchases by members\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eContinuous Feedback Loops\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003eProjected increase in sales of RMB 50 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eShanghai Haohai employs a dedicated direct sales force to reach healthcare professionals and institutions. In 2022, the company's direct sales accounted for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total revenue, which was about \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e out of total sales of \u003cstrong\u003eRMB 2 billion\u003c\/strong\u003e. The sales team consists of over \u003cstrong\u003e200\u003c\/strong\u003e representatives, focusing on building relationships with hospitals and laboratories in China.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platform\u003c\/h3\u003e\n\u003cp\u003eThe company also utilizes an online platform as a significant channel. In 2022, the online sales amounted to \u003cstrong\u003eRMB 400 million\u003c\/strong\u003e, representing \u003cstrong\u003e20%\u003c\/strong\u003e of total revenue. The platform facilitates direct orders, product information dissemination, and customer engagement. With an average annual growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e in online sales over the past three years, the online channel is positioned for further expansion.\u003c\/p\u003e\n\n\u003ch3\u003eDistributors and Wholesalers\u003c\/h3\u003e\n\u003cp\u003eDistributors and wholesalers play a crucial role in reaching a broader market. As of the latest data, Haohai collaborates with over \u003cstrong\u003e50\u003c\/strong\u003e distributors, which contributed about \u003cstrong\u003eRMB 250 million\u003c\/strong\u003e in 2022, accounting for \u003cstrong\u003e12.5%\u003c\/strong\u003e of total revenue. The partnerships with these distributors have been instrumental in penetrating tier-2 and tier-3 cities, where healthcare access and awareness are increasing.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Trade Shows\u003c\/h3\u003e\n\u003cp\u003eParticipation in medical trade shows is another channel utilized by Shanghai Haohai to showcase its products. In 2022, the company attended \u003cstrong\u003e10\u003c\/strong\u003e major trade shows, generating direct leads estimated at \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e. These events allow the company to connect with potential customers and industry partners, facilitating growth in brand recognition and market reach.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eChannel\u003c\/th\u003e\n            \u003cth\u003eContribution to Revenue (RMB)\u003c\/th\u003e\n            \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n            \u003cth\u003eNumber of Personnel\/Partners\u003c\/th\u003e\n            \u003cth\u003eGrowth Rate\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n            \u003ctd\u003e1,200,000,000\u003c\/td\u003e\n            \u003ctd\u003e60%\u003c\/td\u003e\n            \u003ctd\u003e200 Representatives\u003c\/td\u003e\n            \u003ctd\u003eNA\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eOnline Platform\u003c\/td\u003e\n            \u003ctd\u003e400,000,000\u003c\/td\u003e\n            \u003ctd\u003e20%\u003c\/td\u003e\n            \u003ctd\u003eNA\u003c\/td\u003e\n            \u003ctd\u003e15%\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eDistributors and Wholesalers\u003c\/td\u003e\n            \u003ctd\u003e250,000,000\u003c\/td\u003e\n            \u003ctd\u003e12.5%\u003c\/td\u003e\n            \u003ctd\u003e50 Distributors\u003c\/td\u003e\n            \u003ctd\u003eNA\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eMedical Trade Shows\u003c\/td\u003e\n            \u003ctd\u003e100,000,000\u003c\/td\u003e\n            \u003ctd\u003e5%\u003c\/td\u003e\n            \u003ctd\u003e10 Shows\u003c\/td\u003e\n            \u003ctd\u003eNA\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eShanghai Haohai Biological Technology Co., Ltd. serves various customer segments, each with specific needs and requirements in the biotechnology and pharmaceutical sectors.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eHospitals and clinics are significant customer segments for Haohai, with a focus on providing innovative medical solutions. As of 2022, the global healthcare market was valued at approximately \u003cstrong\u003e$11.9 trillion\u003c\/strong\u003e and is projected to reach \u003cstrong\u003e$17.0 trillion\u003c\/strong\u003e by 2028, growing at a CAGR of \u003cstrong\u003e6.8%\u003c\/strong\u003e. This growth influences the demand for biotechnology products and services.\u003c\/p\u003e\n\n\u003ch3\u003eBiotechnology Firms\u003c\/h3\u003e\n\u003cp\u003eHaohai collaborates with various biotechnology firms, which represent a significant customer base. The biotech industry was valued at around \u003cstrong\u003e$752 billion\u003c\/strong\u003e in 2021 and is expected to reach \u003cstrong\u003e$1,506 billion\u003c\/strong\u003e by 2028, exhibiting a CAGR of \u003cstrong\u003e10.8%\u003c\/strong\u003e. These firms depend on Haohai's technological advancements for research, development, and production processes.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eResearch institutions form a crucial part of Haohai's customer segments. In 2021, global R\u0026amp;D spending reached approximately \u003cstrong\u003e$2.4 trillion\u003c\/strong\u003e, with significant investments in biotechnology and pharmaceuticals. These institutions require Haohai's products for their innovative research programs, with funding allocated extensively in health biotechnology.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical companies constitute another essential customer segment. The global pharmaceutical market was valued at about \u003cstrong\u003e$1.48 trillion\u003c\/strong\u003e in 2021 and is projected to grow at a CAGR of \u003cstrong\u003e6.5%\u003c\/strong\u003e to reach \u003cstrong\u003e$2.4 trillion\u003c\/strong\u003e by 2028. Haohai provides various products and solutions tailored to the specific needs of these companies, enabling them to enhance their product pipelines.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eMarket Size (2021)\u003c\/th\u003e\n        \u003cth\u003eProjected Market Size (2028)\u003c\/th\u003e\n        \u003cth\u003eCAGR\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e$11.9 trillion\u003c\/td\u003e\n        \u003ctd\u003e$17.0 trillion\u003c\/td\u003e\n        \u003ctd\u003e6.8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eBiotechnology Firms\u003c\/td\u003e\n        \u003ctd\u003e$752 billion\u003c\/td\u003e\n        \u003ctd\u003e$1,506 billion\u003c\/td\u003e\n        \u003ctd\u003e10.8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003e$2.4 trillion (R\u0026amp;D Spending)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n        \u003ctd\u003e$1.48 trillion\u003c\/td\u003e\n        \u003ctd\u003e$2.4 trillion\u003c\/td\u003e\n        \u003ctd\u003e6.5%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Shanghai Haohai Biological Technology Co., Ltd. encompasses several key components critical to its operations.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eIn the fiscal year 2022, Shanghai Haohai Biological Technology reported approximately \u003cstrong\u003e¥511 million\u003c\/strong\u003e in research and development (R\u0026amp;D) expenditures. This represents around \u003cstrong\u003e15%\u003c\/strong\u003e of the company's total revenue, focusing on developing innovative biological products and technologies.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eManufacturing costs, which include raw materials, labor, and overhead, accounted for about \u003cstrong\u003e50%\u003c\/strong\u003e of total costs in 2022. The total manufacturing expense was approximately \u003cstrong\u003e¥1.5 billion\u003c\/strong\u003e. The company operates several production facilities, with a focus on maintaining quality through adherence to international standards.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Distribution Costs\u003c\/h3\u003e\n\u003cp\u003eMarketing and distribution costs are essential for product placement and brand recognition. In 2022, these costs reached approximately \u003cstrong\u003e¥200 million\u003c\/strong\u003e, which is around \u003cstrong\u003e6%\u003c\/strong\u003e of total revenue. This includes digital marketing efforts, sales personnel expenses, and logistics.\u003c\/p\u003e\n\n\u003ch3\u003eCompliance and Regulatory Fees\u003c\/h3\u003e\n\u003cp\u003eCompliance and regulatory fees, crucial for maintaining licenses and certifications, were approximately \u003cstrong\u003e¥100 million\u003c\/strong\u003e for the year 2022. This amount represents about \u003cstrong\u003e3%\u003c\/strong\u003e of the total operating expenses, reflecting the company’s commitment to meeting strict industry regulations.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Component\u003c\/th\u003e\n    \u003cth\u003eAmount (¥ million)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e511\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1,500\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketing and Distribution Costs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e200\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompliance and Regulatory Fees\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e100\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThe total operational costs reflect the company's strategic investments in growth while ensuring compliance with industry standards and regulations. Each segment of the cost structure plays a crucial role in supporting the overall business objectives of Shanghai Haohai Biological Technology Co., Ltd.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai Haohai Biological Technology Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eShanghai Haohai Biological Technology Co., Ltd. operates in the biopharmaceutical field, primarily focusing on the development and manufacturing of biological products. The company has established several revenue streams that contribute to its financial performance.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eThe primary revenue stream for Shanghai Haohai is through direct product sales, which includes its range of biological products such as surgical sutures, tissue adhesives, and cell culture products. In 2022, the company reported total product sales of \u003cstrong\u003e¥1.7 billion\u003c\/strong\u003e, showing a year-on-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eShanghai Haohai generates revenue through licensing agreements with various pharmaceutical companies. For instance, it entered into a licensing deal for its proprietary products, which accounted for \u003cstrong\u003e¥300 million\u003c\/strong\u003e in revenue in 2022. The total licensing revenue represented approximately \u003cstrong\u003e17%\u003c\/strong\u003e of the company's overall income for that year.\u003c\/p\u003e\n\n\u003ch3\u003eContract Research Services\u003c\/h3\u003e\n\u003cp\u003eContract research services are another significant revenue stream. The company offers services to assist in the development and testing of biological products. In 2022, this segment generated revenue amounting to \u003cstrong\u003e¥400 million\u003c\/strong\u003e, reflecting a growth rate of \u003cstrong\u003e20%\u003c\/strong\u003e from the previous year. The share of contract research services in total revenue was about \u003cstrong\u003e23%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Grants and Subsidies\u003c\/h3\u003e\n\u003cp\u003eShanghai Haohai has also benefited from government grants and subsidies aimed at promoting research and development in the biotechnology sector. In 2022, the company received grants totaling \u003cstrong\u003e¥150 million\u003c\/strong\u003e, which helped fund various innovative projects. These grants represented approximately \u003cstrong\u003e9%\u003c\/strong\u003e of the total revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRevenue Stream\u003c\/th\u003e\n    \u003cth\u003e2022 Revenue (¥ Million)\u003c\/th\u003e\n    \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct Sales\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1,700\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e61\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eContract Research Services\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e400\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e23\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Grants and Subsidies\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e150\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eN\/A\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e9\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese diverse revenue streams help Shanghai Haohai maintain its financial stability and support ongoing research in biological technologies, positioning it for continued growth in a competitive market.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45713846206613,"sku":"6826hk-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/6826hk-business-model-canvas.png?v=1739149682","url":"https:\/\/dcf-model.com\/es\/products\/6826hk-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}